HEP 114

Drug Profile

HEP 114

Alternative Names: HEP-114

Latest Information Update: 12 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TGV-Laboratories
  • Class
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver disorders

Most Recent Events

  • 12 Aug 2017 HEP 114 is still in phase III trials for Liver disorders in Russia (IV) (TGV-Laboratories Pipeline, August 2017)
  • 12 Aug 2017 Preclinical feasibility studies are ongoing in USA (PO, IV) (TGV-Laboratories Pipeline, August 2017)
  • 20 Jan 2016 TGV-Laboratories completes a phase III trial in Liver disorders in Russia (PO) before January 2016 (TGV-Laboratories Pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top